Together theseresults demonstrate the ability to generate heritable specific and permanentmodifications in a mammal using

Together, theseresults demonstrate the ability to generate heritable, specific and permanentmodifications in a mammal using standard microinjection techniques andengineered ZFNs in early-stage embryos. With antibody sales expected to reach $50 billion within five years, manycompanies have entered the biologics market through acquiring antibodytechnologies or licensing/fee for service arrangements. Currently, the mouse isthe only genetically engineered animal commercially available for the generationof human monoclonal antibodies, and many targets are licensed already. Theexpense and limitations of the mouse technology create an opportunity for OMTand its new monoclonal antibody platform with unrestricted development options. OMT`s human antibody technology is the result of an improved understanding ofB-cell development and a novel approach to the inactivation of endogenousantibody expression described in the “Science” article. Previously, it tookeither embryonic stem cells or nuclear transfer cloning — techniques that arenot available for the genetic engineering of rats — to create a knockout, OMTused a new ZFN-mediated technique to generate immunoglobulin knockout rats.

ZFNsare engineered proteins that induce double-strand breaks at specific sites in anorganism`s DNA. Such double-strand breaks stimulate the cell`s naturalDNA-repair pathways and can result in site-specific changes in the DNA sequence.Up to now, ZFNs have been used to edit specific genes in fruit flies, worms (C.elegans), cultured cells and zebrafish embryos, but this is the first example ofsuccessful, permanent, heritable gene-editing in a mammal. About Open Monoclonal Technology, Inc.:Open Monoclonal Technology, Inc. (“OMT”) is a private biotechnology companydeveloping a new, fully human monoclonal antibody platform based on transgenicrats.

The rat is a widely used laboratory animal with a well characterizedimmune system, a nearly complete genome sequence, and established transgenesisand hybridoma technologies. OMT`s antibody platform is the result of an improvedunderstanding of B-cell development and a novel approach to the inactivation ofendogenous antibody expression. The antibody platform is available for alltargets, has broad freedom to operate, and uses technology protected by patents.For more information about OMT, contact Roland Buelow at orvisit http:// to editors/reporters:* After 5 pm ET, July 23, the article may be viewed at * Additional background information is available from , at (“News”).Open Monoclonal Technology, Inc.Dr. Roland Buelow, Or visit, Business Wire 2009.

We believe that as we demonstratefurther the fiscal improvement we should be able to negotiate financingtransactions under more favorable terms for the company.”About Jesup & Lamont, Inc.Established in 1877, Jesup & Lamont, Inc. The first “package” provides comprehensive sales forceautomation (SFA) and customer relationship management (CRM) functionality, whilethe second “package” is geared towards solving the eCommerce needs of smallbusinesses by providing comprehensive eCommerce functionality – such as ordercapture, shopping cart, lists, order and shipping status, etc – all within aproven, scalable solution. Both packages also feature the functionality of Requisite Technology`scomprehensive, channel-specific framework, which includes modules – such asmarketing communications, partner profiles, partner programs, and business plans- designed to help small enterprises improve profitability throughout theirchannel. Both packages also boast quick implementation timelines along withincredibly scalable designs – meaning the solution is agile, responsive, andable to grow with the business when the time is right.